Acted as Rule 3 Adviser, Financial Adviser, Nominated Adviser and Sole Broker

Panmure Gordon is delighted to announce that it has acted as Rule 3 Adviser, Financial Adviser, Nominated Adviser and Sole Broker to Allergy Therapeutics plc on an unconditional mandatory cash offer by its shareholder, ZQ Capital, which valued the company at £48 million.

Allergy Therapeutics plc is an integrated commercial biotechnology company specialising in allergy vaccines.

Deal Team:

Emma Earl

Managing Director, Healthcare, Investment Banking

Rupert Dearden

Managing Director, Corporate Broking Services

Mark Rogers

Vice President, Investment Banking, IBD Advisory

Freddy Crossley

Managing Director, Head of Healthcare

Freddie Wooding

Analyst, Investment Banking

Dr Mike Mitchell

Director, Research Analyst, Healthcare